Physician profile
Michaela E Rutledge
NPI 1609437573
$4,578.10
in general payments reported to CMS, 2019-2025
21 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,270 · 2023: $969 · 2024: $1,885 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,061 · Consulting Fee: $990 · Education: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,060.60 |
| Consulting Fee | $990.00 |
| Education | $257.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,269.57 | 2022 | |
| Incyte Corporation | $1,175.57 | 2023-2025 | Niktimvo, Jakafi |
| Sanofi-Aventis U.S. LLC | $435.22 | 2023-2024 | |
| Janssen Biotech, INC. | $412.52 | 2023-2025 | Darzalex, Tecvayli, Carvykti |
| Adaptive Biotechnologies Corporation | $186.32 | 2023-2024 | Clonoseq |
| Syndax Pharmaceuticals, INC. | $145.28 | 2025 | Revuforj |
| Astrazeneca Pharmaceuticals LP | $123.70 | 2024 | Enhertu |
| Astellas Pharma US INC | $120.62 | 2023-2025 | Cresemba |
| Sobi, INC | $119.05 | 2023 | |
| Glaxosmithkline, LLC. | $110.76 | 2024 | Ojjaara |
| E.R. Squibb & Sons, L.L.C. | $108.06 | 2024 | Opdivo |
| Legend Biotech USA INC. | $94.83 | 2024 | |
| Janssen Scientific Affairs, LLC | $65.03 | 2025 | Carvykti, Talvey |
| Bard Peripheral Vascular, INC. | $51.33 | 2025 | Trek |
| Janssen Pharmaceuticals, INC | $40.31 | 2023 | Xarelto |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $25.83 | 2023 | |
| Merck Sharp & Dohme LLC | $21.98 | 2025 | Prevymis |
| Recordati_rare_diseases_inc. | $20.89 | 2023 | Panhematin |
| Pfizer INC. | $20.35 | 2025 | |
| Karyopharm Therapeutics INC. | $15.84 | 2023 | Xpovio |
| Genmab U.S., INC. | $15.04 | 2023 | Epkinly |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michaela Rutledge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.